Candriam S.C.A.
Institutional investor · Portfolio as of Q1 2019
Top Holdings788 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
MICROSOFT CORP | 1.7M | $205M | 2.6% | $110.82 | 0.00% | 1 qtr | New 79 |
AMGEN INC | 1M | $194.2M | 2.5% | $152.25 | 0.00% | 1 qtr | New 79 |
BIOGEN IDEC INC | 654,495 | $154.7M | 2.0% | $236.38 | 0.00% | 1 qtr | New 69 |
APPLE INC | 758,114 | $149.9M | 1.9% | $45.22 | 0.00% | 1 qtr | New 69 |
REGENERON PHARMACEUTICALS | 347,271 | $142.6M | 1.8% | $408.36 | 0.00% | 1 qtr | New 69 |
ALPHABET INC-CL A | 119,297 | $141.6M | 1.8% | $58.40 | 0.00% | 1 qtr | New 69 |
AMAZON.COM INC | 74,359 | $132.4M | 1.7% | $89.04 | 0.00% | 1 qtr | New 69 |
GILEAD SCIENCES INC | 2M | $131.1M | 1.7% | $50.13 | 0.00% | 1 qtr | New 69 |
MERCK & CO. INC. | 1.6M | $130.4M | 1.7% | $64.32 | 0.00% | 1 qtr | New 69 |
ALIBABA GROUP HOLDING-SP ADR | 682,348 | $124.5M | 1.6% | $171.70 | 0.00% | 1 qtr | New 69 |
VERTEX PHARMACEUTICALS INC | 661,520 | $121.7M | 1.6% | $183.95 | 0.00% | 1 qtr | New 69 |
CELGENE CORP | 1.3M | $118.1M | 1.5% | — | — | 1 qtr | New 69 |
META PLATFORMS INC-CLASS A | 566,232 | $94.4M | 1.2% | $165.53 | 0.00% | 1 qtr | New 68 |
BRISTOL-MYERS SQUIBB CO | 2M | $94.1M | 1.2% | $36.69 | 0.00% | 1 qtr | New 68 |
PROCTER & GAMBLE CO/THE | 722,938 | $79M | 1.0% | $85.93 | 0.00% | 1 qtr | New 68 |
WALT DISNEY CO/THE | 671,243 | $78.6M | 1.0% | $107.17 | 0.00% | 1 qtr | New 68 |
ALEXION PHARMACEUTICALS INC | 565,052 | $76.4M | 1.0% | — | — | 1 qtr | New 58 |
VISA INC-CLASS A SHARES | 444,154 | $73M | 0.9% | $148.12 | 0.00% | 1 qtr | New 58 |
EXXON MOBIL CORP | 812,065 | $71.8M | 0.9% | $58.62 | 0.00% | 1 qtr | New 58 |
ILLUMINA INC | 230,410 | $71.6M | 0.9% | $302.23 | 0.00% | 1 qtr | New 58 |
Candriam S.C.A. manages $7.8B across 788 positions as of Q1 2019. Top holdings: MSFT (2.6%), AMGN (2.5%), BIIB (2.0%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 2/5.0.
Active quarter - 788 new positions, 0 exits, 0 increased. Top move: MSFT (NEW, conviction 79). Portfolio: $7.8B across 788 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer